

1 **Decomposing variation in immune response in a wild rodent population**

2

3 Klara M. Wanelik<sup>1\*</sup>, Mike Begon<sup>1</sup>, Elena Arriero<sup>2,3</sup>, Janette E. Bradley<sup>2</sup>, Ida M. Friberg<sup>4</sup>,

4 Joseph A. Jackson<sup>4</sup>, Christopher H. Taylor<sup>2</sup>, Steve Paterson<sup>1</sup>

5

6 <sup>1</sup> Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom

7 <sup>2</sup> School of Life Sciences, University of Nottingham, Nottingham, United Kingdom

8 <sup>3</sup> Department of Biodiversity, Ecology and Evolution, University Complutense of Madrid,

9 Madrid, Spain

10 <sup>4</sup> School of Environment and Life Sciences, University of Salford, Salford, United Kingdom

11

12 \* Corresponding author

13 Email: [klara.wanelik@liverpool.ac.uk](mailto:klara.wanelik@liverpool.ac.uk) (KMW)

14

15

16

17

18

19

20

21

22

23

24

## 25 **Abstract**

26

27 Individuals vary in their immune response and, as a result, some are more susceptible to  
28 infectious disease than others. Little is known about which components of immune pathways  
29 are responsible for this variation, but understanding these underlying processes could allow  
30 us to predict the outcome of infection for an individual, and to manage their health more  
31 effectively. In this study, we describe transcriptome-wide variation in immune response (to a  
32 standardised challenge) in a wild population of field voles (*Microtus agrestis*). We find that  
33 this variation can be categorised into three main types. We also identify markers, across these  
34 three categories, which display particularly strong individual variation in response. This work  
35 shows how a simple standardised challenge performed on a natural population can reveal  
36 complex patterns of natural variation in immune response.

37

## 38 **Introduction**

39

40 Individuals vary in their immune response. Within a population, some individuals may fail to  
41 make protective immune responses following either natural infection or vaccination and so  
42 are especially vulnerable to infectious disease<sup>1-4</sup>. Defining the patterns of such variability will  
43 enhance our ability to manage the health of individuals – especially those that are most  
44 susceptible to infectious disease in human, livestock or wildlife populations.

45

46 Studies in laboratory mice are the cornerstone of immunology and have provided a detailed  
47 understanding of the molecular and cellular pathways by which immune responses are  
48 effected. This impressive mechanistic understanding, however, has only been achieved by  
49 minimising genetic and environmental variation within a laboratory setting. Where laboratory

50 studies have examined the effects of variability – in genetics, microbiota or diet – both  
51 qualitative and quantitative differences in immune responses have been observed, with  
52 consequent effects on infection<sup>5-7</sup>. Nevertheless, natural variability cannot be fully  
53 reproduced in the laboratory, which has led to a recent effort to characterise the immune  
54 response in wild populations of mice or other rodents. Recent work in mice from agricultural  
55 and other anthropogenic settings is consistent with the expectation that exposure to complex  
56 environments greatly alters immune function<sup>8</sup>. New populations of memory T cells, present  
57 only in non-laboratory mice, have also been identified<sup>9</sup>.

58

59 One commonly used measure of an immune response is to assess the amount of one or more  
60 markers (e.g. transcripts or proteins) produced by a population of cells following stimulation  
61 by an immune agonist. From this *ex vivo* assay, one can gain insight into the types of immune  
62 response that could be made to a pathogen *in vivo*. Such responses depend on the cell types,  
63 the time points and the immune agonist used. Nevertheless, for any molecular marker with  
64 such a response, individuals, in natural populations especially, could exhibit different marker  
65 abundances prior to and/or following stimulation, leading to differences in their response to  
66 stimulation (here defined as the difference between marker abundances prior to and following  
67 stimulation). Furthermore, the most useful (and interesting) markers, in terms of  
68 understanding why individuals vary in their ability to mount a successful immune response,  
69 will be those for which response is most variable among individuals. In the laboratory, cell  
70 populations are usually controlled, or at least well defined, so a difference in the abundance  
71 of a particular marker can be attributed to differences in the activity of a particular cell type.  
72 However, natural variability in the abundance of a marker, and by extension in the response  
73 of individuals in the wild, could result from (i) differences in the composition of cell  
74 populations, and/or (ii) differences in the activity levels of particular cell types. Both of these

75 components have the potential to shape the way an individual responds to immune challenge  
76 in the wild. Our intention here is not to distinguish between the two, but rather to propose a  
77 categorisation of responses, however generated.

78

79 We use a wild population of field voles (*Microtus agrestis*) to examine naturally occurring  
80 patterns of individual variation in immune response, across the transcriptome, as a first step  
81 towards furthering our understanding of the processes driving these patterns. The field  
82 population we study, in Kielder Forest Northumberland, has been the subject of extensive  
83 previous study on population ecology and pathogen dynamics<sup>10-13</sup>. Therefore, it allows us to  
84 place our existing understanding of more established immunological mechanisms (largely  
85 derived from the closely related laboratory mouse, *Mus musculus*) into a well-described, real-  
86 world context.

87

88 We describe three main categories of immune response: (i) uncorrelated response, (ii)  
89 constant response and (iii) baseline-dependent response (depicted in Fig. 1). We also identify  
90 markers, across these categories, which show particularly high inter-individual variability in  
91 response. We suggest that such categorisation is useful in organising natural immune  
92 variation, since little is known about which components of immune pathways are responsible  
93 for natural variability in immune response, or about the nature and possible causes of such  
94 variability. Indeed, this categorisation is not limited to the components of conventional  
95 immune pathways. The ability of an immune response to effect protection against infection,  
96 for example, will be supported by a variety of non-immune functions, that will also be  
97 activated following stimulation by an agonist, and vary to a greater or lesser extent among  
98 individuals within a natural population. By identifying the components (whether  
99 conventionally immunological or not) that are likely to be responsible for natural variability

100 in immune response, and by describing the nature of their variability, we are laying the  
101 groundwork for exploring the processes, whether genetic or environmental, which drive inter-  
102 individual variation in immune response.

103

## 104 **Results**

105

### 106 **Stimulation with an immune agonist causes a widespread response**

107 Spleen cells from sixty-two field voles were split into two populations per individual vole.  
108 One population was stimulated with anti-CD3 and anti-CD28 antibodies, while the other was  
109 kept as an unstimulated control (hereafter referred to as the baseline). 1150 transcripts (5% of  
110 all genes in the field vole genome and 85% of informative genes, those genes which were  
111 more strongly expressed; see Methods) fell into one or more of the response categories set  
112 out in Fig. 1. As expected, given that these antibodies are known to stimulate T-cell  
113 proliferation<sup>14</sup>, they were enriched with transcripts (hereafter markers) associated with the T-  
114 cell receptor (TCR) signalling pathway ( $n = 27$ ;  $p < 0.001$ ; Functional Enrichment Analysis  
115 performed in DAVID; see Methods) and other T cell-related terms: positive regulation of T-  
116 cell proliferation ( $n = 12$ ;  $p < 0.03$ ), TCR complex ( $n = 7$ ;  $p < 0.001$ ), positive thymic T-cell  
117 selection ( $n = 7$ ;  $p < 0.01$ ), negative thymic T-cell selection ( $n = 6$ ;  $p = 0.03$ ) and alpha-beta  
118 TCR complex ( $n = 5$ ;  $p < 0.001$ ). For the majority of these markers, a significant positive  
119 linear relationship was found between baseline and stimulated abundance ( $n = 844$ ). Only a  
120 single marker, *Fam193b*, demonstrated a significant negative linear relationship between  
121 baseline and stimulated abundance.

122

123

124

125 **There are three main categories of immune response**

126 Three main categories of immune response were identified based on the dependence of an  
127 individual's response on its baseline abundance. Each of these categories demonstrates a  
128 unique pattern (Fig. 1):

129

130 **Uncorrelated response:** markers for which individuals taken from the wild differ in their  
131 baseline abundance, but the responses of different individuals are variable and independent of  
132 their baseline, such that the slope of the relationship between baseline and stimulated  
133 abundance is not significantly different from zero.

134

135 **Constant response:** markers for which individuals taken from the wild also differ in their  
136 baseline abundance, but the responses of different individuals are (approximately) constant  
137 and independent of their baseline, such that the slope of the relationship between baseline and  
138 stimulated abundance is not significantly different from one and the intercept (indicating the  
139 level of response) is significantly greater than zero.

140

141 **Baseline-dependent response:** markers for which individuals taken from the wild again  
142 differ in their baseline abundance, but the responses of different individuals vary as a  
143 function of their baseline level, either as a linear function of their baseline level (slope  
144 significantly different from one), or as a quadratic function of their baseline level, where  
145 stimulated levels either increase exponentially as a function of baseline levels or become  
146 saturated at some upper limit.

147

148 We also identified markers, across these three categories, for which variability in baseline  
149 and stimulated samples was significantly different, leading to high inter-individual variability  
150 in response (see Methods). These can be divided into two categories (Fig. 1):

151

152 **Convergent response:** markers for which variability in baseline abundance is significantly  
153 greater than variability in stimulated abundance.

154

155 **Divergent response:** markers for which variability in stimulated abundance is significantly  
156 greater than variability in baseline abundance.

157

158 **The baseline-dependent response category is most common and is significantly enriched**  
159 **in components of conventional immune pathways**

160 The baseline-dependent response category was the most common (Table 1), and included a  
161 majority of markers for which stimulated levels were a linear function of baseline levels ( $n =$   
162 539), and a remainder for which they were a quadratic function ( $n = 160$ ). The majority of  
163 quadratic response markers showed evidence for saturation ( $n = 138$ ), indicating some upper  
164 limit on stimulated abundance. The general ontology term for immunity was enriched in the  
165 linear response category of markers ( $n = 20$ ;  $p < 0.01$ ). The TCR signaling pathway was  
166 enriched in the quadratic response category ( $n = 7$ ;  $p = 0.01$ ; Fig. 2).

167

168 **The uncorrelated response category is least common and lacks enrichment in**  
169 **components of conventional immune pathways**

170 A number of markers showed no evidence for a relationship between baseline and stimulated  
171 abundance ( $n = 47$ ; Table 1). For the majority of these, mean abundance was significantly  
172 greater for stimulated than for baseline samples ( $n = 39$ ), suggesting that these markers were

173 (on average) responding to stimulation, but to an individually variable degree, independent of  
174 baseline levels. These markers lacked any enrichment for immune-related terms (Fig. 2).

175

176 **A number of markers, including *Zap70*, show particularly high inter-individual**  
177 **variability in response**

178 For a number of markers, variability in baseline and stimulated abundance was significantly  
179 different, leading to high inter-individual variability in response ( $n = 244$ ). The vast majority  
180 of these markers showed a divergent ( $n = 237$ ), rather than a convergent ( $n = 7$ ) response  
181 (Table 1). Within the (stimulated) TCR signalling pathway, the highest level of variability in  
182 individual response, and the highest level of divergence, was demonstrated by *Zap70* (Fig. 3).  
183 All convergent markers fell into one of the three main immune response categories. However,  
184 over a third of divergent markers ( $n = 98$ ), did not fall into any of these categories, appearing  
185 instead as markers which (on average) did not respond to stimulation (Table 1). Mean  
186 abundances for these markers were also not significantly different between stimulated and  
187 baseline samples.

188

189 **Juveniles show more inter-individual variability in response than adults**

190 An age-specific analysis, run separately on samples from mature ( $n = 43$ ) and juvenile ( $n =$   
191 19) field voles, showed that higher inter-individual variability in immune response (whether  
192 divergent or convergent) was more common among juvenile voles (no. divergent markers =  
193 108; no. convergent markers = 6) than mature voles (randomly sampled 1000 times as more  
194 samples available; mean no. divergent markers = 50, empirical 95% interval = 0–338.2; mean  
195 no. of convergent markers = 0.11, empirical 95% interval = 0–1).

196

197



198 **Response to stimulation is not limited to components of conventional immune pathways**

199 Non-immune related terms were enriched in the baseline-dependent response category,  
200 including: insulin signalling pathway ( $n = 9$ ;  $p = 0.05$ ) and thyroid hormone signalling  
201 pathway ( $n = 8$ ;  $p = 0.05$ ). The top convergent response marker, *Pdk1*, is also a component of  
202 the insulin signalling pathway (Fig. 2).

203

204 **Discussion**

205

206 The need to better understand variation in immune response in natural populations is now  
207 widely accepted<sup>15-18</sup>. Our understanding of immune responses in laboratory settings comes  
208 from animals that vary little either genetically or in prior experience. By contrast, animals in  
209 natural populations vary (perhaps extensively) in both of these. In this study, we describe  
210 natural variation in immune response in a wild population of rodents, and find that it can be  
211 categorised into a limited number of types. We identify three main categories of immune  
212 response: uncorrelated response, constant response and baseline-dependent response. We also  
213 identify markers, across these categories, which show particularly high inter-individual  
214 variability in response. Our work shows how a simple stimulatory assay performed on a  
215 natural population can reveal underlying patterns of natural variation among individuals in  
216 immune response.

217

218 The baseline-dependent response category is the largest. Markers in this category show a  
219 relationship between baseline and stimulated abundance across individuals, and their  
220 response to stimulation is (to a lesser or a greater extent) dependent on their baseline level. In  
221 some cases, individuals already expressing the greatest abundance of a marker in their natural  
222 setting went on to exhibit the greatest response to stimulation by an agonist. In others, the

223 opposite was true, and these individuals exhibited the smallest response to stimulation.  
224 Similarly, previous work on humans has identified baseline (transcriptional) predictors of  
225 influenza vaccination response<sup>19,20</sup>. These differences in baseline level could be driven by  
226 either genetic variation or individual differences in past experience. In humans, genetic  
227 determinants of baseline immune cell population frequencies have been identified<sup>21</sup>. Even  
228 though the stimulation we describe here was not antigen specific, previous challenge by a  
229 parasite might also lead to changes in the baseline T-cell population within an individual's  
230 spleen, affecting its response to any subsequent challenge. In fact, we find that voles infected  
231 with *Babesia microti* (a blood parasite, common in our population<sup>22</sup>) have larger spleens than  
232 uninfected voles<sup>13</sup>. This prior experience may prime an individual, enabling a greater  
233 response to subsequent challenge (e.g. slope greater than one; Fig. 1). However, individuals  
234 may also have an upper limit on the number of immune cells they have available<sup>23,24</sup>. An  
235 individual that is already mounting an immune response to a parasite, and has a large number  
236 of activated T cells, could therefore respond less to a similar challenge than an  
237 'immunologically naïve' individual (slope less than one; Fig. 1). Membership of the baseline-  
238 dependent response category recapitulates the known biology of the immune response (being  
239 highly enriched for immune ontogeny terms). In doing so, it validates the approach we use  
240 here, as a way of identifying markers of immune significance.

241

242 In some cases, individuals varied in their natural abundance of a marker but their response  
243 was unrelated to this. They did nevertheless respond to stimulation, with the majority of these  
244 markers occurring at a significantly higher mean abundance in stimulated samples than in  
245 baseline samples. This uncorrelated response category, which contains a moderate number of  
246 markers, also lacks any enrichment for immune-related ontology terms. This suggests that  
247 markers in this category are not conventional immune markers but could be of immune

248 significance. We warn against omitting such markers from studies of immune response in the  
249 laboratory. They could play an important part in our understanding of the immune response,  
250 indicating for example, genetic variation in response among individuals, which is  
251 independent of baseline level.

252

253 Cutting across this categorisation, a large number of markers displayed a pattern in which  
254 variation between individuals was particularly strong. We describe two types of such  
255 markers, both of which could be used in future studies as indicators of natural variability in  
256 immune response. Markers in the less common, convergent, response category showed much  
257 greater variation naturally than following stimulation. This pattern may be characteristic of  
258 markers showing variable levels of prior activation, coupled with some maximum or  
259 optimum abundance, and resulting in a stabilisation of the immune response across the  
260 population following stimulation. We found that convergent patterns were more common  
261 among juvenile voles. This could suggest that they are more constrained in the energy they  
262 have available (as a result of the competing energetic demands of growth and development)  
263 or the number of immune cells they have available (as a result of a developing immune  
264 system). Either resource constraint could result in a maximum abundance, making them more  
265 inclined to converge. Due to the costly nature of the immune response, individuals often  
266 trade-off their investment in different arms of the immune system<sup>25,26</sup>. Different types of  
267 immune response are therefore likely to be associated with different optimum abundances (or  
268 regions) and an individual already mounting an immune response, but to a different type of  
269 challenge (associated with different cell types), may respond by down-regulating expression.  
270  
271 Divergent markers, which were more common, showed much greater variation following  
272 stimulation than there was naturally. This pattern may be characteristic of (but not limited to)

273 markers showing genetic variation in response to the agonist, independent of baseline levels  
274 e.g. subsets of animals that appear similar but respond more strongly to stimulation than  
275 others. Our own recent work, where we found an association between polymorphism in a  
276 single gene and a marker of a more tolerant immune response<sup>27</sup>, is an example of such  
277 genetic variation in immune response. Further supporting this hypothesis, here, we found  
278 more divergent markers among juvenile voles than mature voles. Younger voles are expected  
279 to have less variable exposure histories, as a result of their shorter life spans, making it easier  
280 to detect genetic effects. Equally, though, divergent patterns could be the result of differences  
281 in early life experiences. One would also expect these to be more easily detectable in  
282 juveniles.

283

284 The divergent category (predominantly) included markers for which individuals made (on  
285 average) the same response to stimulation and markers that did not respond (on average) to  
286 stimulation. Standard differential expression analysis would miss the individual variation  
287 present in the former group, and would fail to pick up the latter group of markers altogether.  
288 Both warn against looking at average (population-level) response, and point instead, to the  
289 value of looking at individual-level differences in immune response. This is particularly  
290 important because divergent markers may act as critical regulators of pathways. For example,  
291 *Zap70*, which demonstrates particularly high levels of variability in individual response and  
292 is centrally located in the TCR signalling pathway, interacts with many other markers (Fig.  
293 3). We suggest that *Zap70* expression could be used as a marker of response in larger studies.  
294 Indeed, it is already linked to major seasonal immune variation in wild fish<sup>28</sup> and is being  
295 used as a prognostic marker for B-cell chronic lymphocytic leukemia in humans, with  
296 potential implications for determining a patient's treatment path (recently reviewed in Liu *et*  
297 *al.*<sup>29</sup>). Other potential prognostic (or diagnostic) factors which may have been missed using

298 standard differential expression analyses may be present in this category and warrant further  
299 investigation.

300

301 The immune response categories we describe here are based on spleen cells stimulated with  
302 anti-CD28 and anti-CD3 antibodies and sampled at 24 hours. However, the relative  
303 frequency of the response categories reported here may vary depending on the choice of  
304 agonist and/or time point. For example, markers are known to follow different response  
305 trajectories, with some immediately responding and reaching peak activation, and others  
306 taking longer to reach this point<sup>30</sup>. Sampling at a later time point, then, when the ‘slower’  
307 markers have reached peak activation, may lead to more convergence than reported here. In  
308 order to fully account for this temporal variation, multiple time points need to be averaged  
309 across. We argue that both time-specific and averaged responses are of functional  
310 significance, but hope others will extend our work. We use RNASeq here in order to give a  
311 broad view of the immune response. Single-cell RNASeq could be used to quantify  
312 differences in individual response resulting solely from differences in cell-specific activity.  
313 Previous work has shown that transcript levels generally correlate with protein levels across  
314 genes<sup>31</sup>. However, more work is needed to confirm these response categories at the functional  
315 level<sup>32</sup>. In future, Q-PCR or protein-level data could be used in order to include weakly  
316 expressed markers, which were excluded here as a result of the heteroscedasticity inherent in  
317 RNASeq data.

318

319 Markers that responded to stimulation were not limited to immune pathways as  
320 conventionally defined. They included, for example, markers involved in the insulin  
321 signalling pathway. This is in line with previous studies, which suggest that insulin plays a  
322 key role in coordinating an organism’s response to infection, influencing, in particular, the

323 allocation of resources<sup>33,34</sup>. One of these markers, *Pdk1*, was also among the top convergent  
324 markers. This could be representative of the high levels of variability in the (baseline)  
325 nutritional status of individuals in a natural population, coupled with an upper limit on the  
326 processes involved in glucose metabolism.

327

328 The immune categories we presented here, therefore, highlight markers not traditionally  
329 associated with immune functions, and offer a promising avenue for identifying potential  
330 prognostic (or diagnostic) factors for disease, like *Zap70*. They also point to both genetics  
331 and prior experience as drivers of natural variation in immune response. Our future work will  
332 further decompose this natural variation into that driven by these two components.

333

## 334 **Methods**

335

### 336 **Field methods**

337 Sixty-two field voles were collected between July and October 2015 to assay expression by  
338 RNASeq. These voles came from four sites in Kielder Forest, Northumberland (55°130N,  
339 2°330W). Each site contained a trapping grid of regularly spaced traps (at approx. 5 m  
340 intervals) and was also used for other components of a larger field study (for more details see  
341 Wanelik *et al.*<sup>27</sup>).

342

### 343 **Ethics statement**

344 All animal procedures, carried out as part of this field study, were performed with approval  
345 from the University of Liverpool Welfare Committee and under the authority of the UK  
346 Home Office (Animals (Scientific Procedures) Act 1986) project licence number PPL

347 70/8210 to SP. Voles were killed by a rising concentration of CO<sub>2</sub> followed by  
348 exsanguination.

349

### 350 **Cell culture methods**

351 Splenocyte cultures from each vole were split into two populations, one of which was  
352 stimulated with anti-CD3 antibodies (Hamster Anti-Mouse CD3e, Clone 500A2 from BD  
353 Pharmingen) and anti-CD28 antibodies (Hamster Anti-Mouse CD28, Clone 37.51 from BD  
354 Tombo Biosciences) at concentrations of 2 µg/ml and of 1 µg/ml respectively for 24hr, and  
355 the other was left as an unstimulated control to act as a reference level. We refer to this  
356 reference level as the baseline, and control samples as baseline samples. However, it is  
357 important to note that this level will vary for an individual, not only on a day to day basis, but  
358 throughout its life. Culture conditions were otherwise equivalent to those used in Jackson *et*  
359 *al.* (2011)<sup>35</sup>. Costimulation with anti-CD3 and anti-CD28 antibodies was used to selectively  
360 promote the proliferation of T cells<sup>14</sup>, our assumption being that this would reflect the  
361 potential response of T-cell populations *in vivo*. Cell populations within splenocyte cultures  
362 were variable but left undefined.

363

### 364 **RNASeq preparation and mapping**

365 RNA was extracted using Invitrogen PureLink kits. Following extraction, cDNA libraries  
366 were prepared using Illumina RiboZero kits and libraries were constructed with NEBNext  
367 Ultra directional RNA library prep kit according to the manufacturers protocols. Samples  
368 were sequenced to produce 2 x 75 bp paired-end reads on an Illumina HiSeq4000 platform.  
369 Adaptor sequences were removed with CUTADAPT version 1.2. and further trimmed with  
370 SICKLE version 1.200 (minimum window quality score of 20). This resulted in a mean  
371 library size of 18 million (range = 5–50 million) paired-end reads.

372

373 High-quality reads were mapped against a draft genome for *M. agrestis* (GenBank Accession  
374 no. LIQJ000000000) using TOPHAT version 2.1.0, and a set of predicted gene models was  
375 generated using BRAKER. Mapped reads were counted using FEATURECOUNTS. Further  
376 analysis was performed on counts of mapped reads for each gene in R version 3.4.2<sup>36</sup>. These  
377 count data were initially filtered to remove unexpressed genes (those genes with fewer than  
378 three counts per million across all samples;  $n = 13$ ). Following filtering, library sizes were  
379 recalculated and data were normalised to represent counts per million (cpm). These data were  
380 found to be correlated with quantitative PCR (Q-PCR) data (see Supplementary Fig. 1). No  
381 correction for gene length was necessary as all analyses were based on comparisons across  
382 (rather than within) samples. Transcript abundance for a particular gene here represents a  
383 single, functional measure of its activity across some, undefined, cell population. In order to  
384 maximise the power of our analysis to identify biologically relevant patterns, we focussed on  
385 those genes which were expressed at an informative level in the spleen prior to and/or  
386 following stimulation ( $n = 1350$  or 6%). Genes expressed at a mean level greater than 200  
387 cpm were considered informative. As weakly expressed genes were removed (minimising  
388 heteroscedasticity), log-transformation of data was unnecessary (Supplementary Fig. 2).

389

### 390 **Statistical analysis**

391 Genes for which a response to stimulation was observed across individuals were identified,  
392 and, as elaborated in the Results, categorised on the basis of (i) the dependence of an  
393 individual's response on its baseline level, and (ii) the degree of inter-individual variability in  
394 response across individuals.

395



396 **Baseline-dependence of response.** The dependence of an individual's response on its  
397 baseline level was quantified by testing the relationship between that individual's baseline  
398 abundance ( $\text{cpm}_{\text{base}}$ ) and its stimulated abundance ( $\text{cpm}_{\text{stim}}$ ) using a linear regression, taking  
399 the form

400

$$401 \quad \text{cpm}_{\text{stim}} \sim \text{cpm}_{\text{base}}$$

402

403 as well as a quadratic regression, taking the form

404

$$405 \quad \text{cpm}_{\text{stim}} \sim \text{cpm}_{\text{base}} + \text{cpm}_{\text{base}}^2$$

405

406 For approximately one third of genes ( $n = 466$ ), the residuals from both of these regressions  
407 deviated significantly from the assumptions of normality and/or homoscedasticity, and a non-  
408 parametric Kendall–Theil linear regression was fitted instead. Regression fits varied from  
409 gene to gene ( $R^2$  ranging from  $<0.001$  to  $0.85$ ).

410

411 **Inter-individual variability in response.** Inter-individual variability in response was  
412 quantified by comparing the coefficient of variation (CV) for baseline abundances across  
413 individuals ( $\text{CV}_{\text{base}}$ ) and the CV for stimulated abundances across individuals ( $\text{CV}_{\text{stim}}$ ). As  
414 response is defined as the difference between baseline and stimulated abundance, a large  
415 difference in their CVs, either

416

$$417 \quad \text{CV}_{\text{base}} > \text{CV}_{\text{stim}}$$

417

418 or

$$CV_{\text{stim}} > CV_{\text{base}}$$

419

420 indicates a high level of variability in response. A relationship between gene-wise mean  
421 expression levels and CV is typically found in RNASeq data, with low mean transcript  
422 abundance being strongly associated with high variability<sup>37</sup>. As we restricted our analysis to  
423 informative genes only, excluding those genes with low mean abundance, it was not  
424 necessary to account for this relationship (Supplementary Fig. 2). Asymptotic tests for the  
425 equality of CVs were run using the cvequality package. All *p*-values were corrected for  
426 multiple testing using the Benjamini-Hochberg method<sup>38</sup>.

427

428 **Functional annotation.** Functional enrichment analyses were run using The Database for  
429 Annotation, Visualization and Integrated Discovery (DAVID) version 6.8<sup>39,40</sup>. Benjamini-  
430 Hochberg corrected *p*-values and gene counts are reported alongside ontology terms,  
431 including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to indicate their  
432 level of enrichment<sup>41-43</sup>.

433

434 **Age-specific analysis.** In order to begin to investigate the relative importance of genetic  
435 variation versus prior stimulation for shaping patterns of variation in immune response, the  
436 same analysis was performed separately on juvenile and mature voles. As we had more  
437 samples from mature voles ( $n = 43$ ) than juvenile voles ( $n = 19$ ), we randomly sampled the  
438 mature population (with replacement) 1000 times and averaged across these samples. The  
439 number (juveniles) or mean number (matures) of genes in each of these age classes is  
440 presented in the text.

441

442

## 443 **References**

444

- 445 1. Sarre, C. *et al.* Comparative immune responses against *Psoroptes ovis* in two cattle  
446 breeds with different susceptibility to mange. *Vet. Res.* **46** (2015).
- 447 2. Mahler, M., Janke, C., Wagner, S. & Hedrich, H. J. Differential susceptibility of  
448 inbred mouse strains to *Helicobacter pylori* infection. *Scand. J. Gastroenterol.* **37**,  
449 267–278 (2002).
- 450 3. Eugui, E. M. & Allison, A. C. Malaria infections in different strains of mice and their  
451 correlation with natural killer activity. *Bull. World Health Organ.* **57**, 231–238 (1979).
- 452 4. Brodin, P. *et al.* Variation in the human immune system is largely driven by non-  
453 heritable influences. *Cell* **160**, 37–47 (2015).
- 454 5. Sellers, R. S., Clifford, C. B., Treuting, P. M. & Brayton, C. Immunological variation  
455 between inbred laboratory mouse strains: points to consider in phenotyping genetically  
456 immunomodified mice. *Vet. Pathol.* **49**, 32–43 (2012).
- 457 6. Lochmiller, R. L., Vestey, M. R. & Nash, D. Gut associated lymphoid tissue in the  
458 cotton rat (*Sigmodon hispidus*) and its response to protein restriction. *J. Wildl. Dis.* **28**,  
459 1–9 (1992).
- 460 7. Hooper, L. V, Littman, D. R. & Macpherson, A. J. Interactions between the microbiota  
461 and the immune system. *Science* **336**, 1268–1273 (2012).
- 462 8. Abolins, S. R., Pocock, M. J., Hafalla, J. C., Riley, E. M. & Viney, M. E. Measures of  
463 immune function of wild mice, *Mus musculus*. *Mol. Ecol.* **20**, 881–892 (2011).
- 464 9. Beura, L. K. *et al.* Normalizing the environment recapitulates adult human immune  
465 traits in laboratory mice. *Nature* **532**, 512–516 (2016).
- 466 10. Burthe, S. *et al.* Cowpox virus infection in natural field vole *Microtus agrestis*  
467 populations: delayed density dependence and individual risk. *J. Anim. Ecol.* **75**, 1416–

- 468           1425 (2006).
- 469   11.   Smith, A., Telfer, S., Burthe, S., Bennett, M. & Begon, M. Trypanosomes, fleas and  
470       field voles: ecological dynamics of a host-vector--parasite interaction. *Parasitology*  
471       **131**, 355–365 (2005).
- 472   12.   Telfer, S. *et al.* Species interactions in a parasite community drive infection risk in a  
473       wildlife population. *Science* **330**, 243–246 (2010).
- 474   13.   Taylor, C. H. *et al.* Physiological, but not fitness, effects of two interacting  
475       haemoparasitic infections in a wild rodent. *Int. J. Parasitol.* **48**, 463–471 (2018).
- 476   14.   Frauwirth, K. A. & Thompson, C. B. Lymphocyte signal transduction activation and  
477       inhibition of lymphocytes by costimulation. *Cancer Res.* **109**, 295–299 (2002).
- 478   15.   Pedersen, A. B. & Babayan, S. A. Wild immunology. *Mol. Ecol.* **20**, 872–880 (2011).
- 479   16.   Viney, M. & Riley, E. M. The immunology of wild rodents: current status and future  
480       prospects. *Front. Immunol.* **8**, 1–9 (2017).
- 481   17.   Turner, A. K. & Paterson, S. Wild rodents as a model to discover genes and pathways  
482       underlying natural variation in infectious disease susceptibility. *Parasite Immunol.* **35**,  
483       386–395 (2013).
- 484   18.   Jackson, J. A. *et al.* Immunomodulatory parasites and toll-like receptor-mediated  
485       tumour necrosis factor alpha responsiveness in wild mammals. *BMC Biol.* **7**, 16  
486       (2009).
- 487   19.   Tsang, J., Schwartzberg, P., Kotliarov, Y. & Al., E. Global analyses of human immune  
488       variation reveal baseline predictors of post-vaccination responses. *Cell* **157**, 499–513  
489       (2014).
- 490   20.   IPC-CHI Signatures Project Team & HIPC-I Consortium. Multicohort analysis reveals  
491       baseline transcriptional predictors of influenza vaccination responses. *Sci. Immunol.* **2**,  
492       eaal4656 (2017).

- 493 21. Orrù, V. *et al.* Genetic variants regulating immune cell levels in health and disease.  
494 *Cell* **155**, 242–256 (2013).
- 495 22. Telfer, S. *et al.* Parasite interactions in natural populations: insights from longitudinal  
496 data. *Parasitology* **135**, 767–781 (2010).
- 497 23. Sheldon, B. C. & Verhulst, S. Ecological immunology: costly parasite defences and  
498 trade-offs in evolutionary ecology. *Trends Ecol. Evol.* **11**, 317–321 (1996).
- 499 24. Lochmiller, R. L. & Deerenberg, C. Trade-offs in evolutionary immunology: just what  
500 is the cost of immunity? *Oikos* **88**, 87–98 (2000).
- 501 25. Reiner, S. L. Development in motion: helper T cells at work. *Cell* **129**, 33–36 (2007).
- 502 26. Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T  
503 lymphocytes. *Nature* **383**, 787–793 (1996).
- 504 27. Wanelik, K. M. *et al.* A candidate tolerance gene identified in a natural population of  
505 field voles (*Microtus agrestis*). *Mol. Ecol.* **27**, 1044–1052 (2018).
- 506 28. Brown, M. *et al.* Seasonal immunoregulation in a naturally-occurring vertebrate. *BMC*  
507 *Genomics* **17** (2016).
- 508 29. Liu, Y., Wang, Y., Yang, J., Bi, Y. & Wang, H. ZAP-70 in chronic lymphocytic  
509 leukemia: a meta-analysis. *Clin. Chim. Acta* **483**, 82–88 (2018).
- 510 30. Tate, A. T. & Graham, A. L. Dissecting the contributions of time and microbe density  
511 to variation in immune gene expression. *Proc. R. Soc. B Biol. Sci.* **284** (2017).
- 512 31. Tian, Q. *et al.* Integrated genomic and proteomic analyses of gene expression in  
513 mammalian cells. *Mol. Cell. Proteomics* **3**, 960–969 (2004).
- 514 32. Viney, M. E., Riley, E. M. & Buchanan, K. L. Optimal immune responses:  
515 immunocompetence revisited. *Trends Ecol. Evol.* **20**, 665–669 (2005).
- 516 33. Garcia, N. W. *et al.* Exogenous insulin enhances humoral immune responses in short-  
517 day, but not longday, Siberian hamsters (*Phodopus sungorus*). *Proc. R. Soc. B Biol.*

- 518           *Sci.* **277**, 2211–2218 (2010).
- 519   34.   Lee, S. *et al.* Modulatory upregulation of an insulin peptide gene by different  
520           pathogens in *C. elegans*. *Virulence* **9**, 648–658 (2018).
- 521   35.   Jackson, J. A. *et al.* The analysis of immunological profiles in wild animals: a case  
522           study on immunodynamics in the field vole, *Microtus agrestis*. *Mol. Ecol.* **20**, 893–909  
523           (2011).
- 524   36.   R Core Team. R: A language and environment for statistical computing. R Foundation  
525           for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>. (2016).
- 526   37.   Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. Voom: Precision weights unlock linear  
527           model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, 1–17 (2014).
- 528   38.   Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and  
529           powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
- 530   39.   Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools:  
531           paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids*  
532           *Res.* **37**, 1–13 (2009).
- 533   40.   Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis  
534           of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57  
535           (2009).
- 536   41.   Kanehisa, M. & Goto, S. KEGG; Kyoto Encyclopedia of Genes and Genomes. *Nucleic*  
537           *Acids Res.* **28**, 27–30 (2000).
- 538   42.   Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a  
539           reference resource for gene and protein annotation. *Nucleic Acids Res.* **44**, D457–D462  
540           (2016).
- 541   43.   Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: New  
542           perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* **45**, D353–

543 D361 (2017).

544

## 545 **Acknowledgements**

546 The authors wish to thank those involved in obtaining and processing samples from the field:

547 Rebecca Turner, Lukasz Lukomski, Stephen Price, William Foster, Ann Lowe and Anna

548 Thomason. They also wish to thank the Forestry Commission for access to the study sites and

549 the Centre for Genomic Research at the University of Liverpool for sequencing samples.

550

## 551 **Author contributions**

552 M.B., J.E.B., J.A.J. and S.P. designed the study. E.A. undertook the stimulatory assays.

553 K.M.W. analysed the data. All authors wrote the manuscript.

554

## 555 **Competing interest statement**

556 The authors declare no competing financial interests.

557

## 558 **Figure captions**

559

560 **Fig. 1 Different categories of immune response.** These are based on two overlapping sets

561 of criteria, baseline-dependence of response (blue) and inter-individual variability in response

562 (yellow background). Arrows represent individual immune responses. No response (for

563 reference): markers for which individuals (on average) show no response to stimulation

564 (intercept not significantly different from zero; slope not significantly different from one).

565 Uncorrelated response: markers for which responses of different individuals are variable and

566 independent of their baseline level (slope not significantly different from zero). Constant

567 response: markers for which the responses of different individuals response are  
568 (approximately) constant and independent of their baseline (intercept significantly greater  
569 than zero; slope not significantly different from one). Baseline-dependent response: markers  
570 for which responses of different individuals vary as a function of their baseline level, either  
571 as a linear function of their baseline (slope significantly different from one; slope greater than  
572 one is depicted but could equally be less than one), or as a quadratic function of their baseline  
573 (a saturating function is depicted but could equally be exponential). Convergent response:  
574 markers for which the coefficient of variation (CV) for baseline abundances is significantly  
575 greater than the CV for stimulated abundances across individuals ( $CV_{\text{base}} > CV_{\text{stim}}$ ).  
576 Divergent response: markers for which CV for stimulated abundances is significantly greater  
577 than CV for baseline abundances across individuals ( $CV_{\text{stim}} > CV_{\text{base}}$ ). Both convergent and  
578 divergent markers depicted as, but not limited to, markers for which response is uncorrelated.  
579

580 **Fig. 2 Top 10 markers and enriched ontology terms in each immune response category.**

581 Each box represents a category of immune response (as in Fig. 1). For each category,  
582 top 10 annotated markers for which we had the most confidence in their categorisation  
583 (markers were ranked on  $R^2$  and  $p$ -values) are listed, one or two of these are represented in  
584 plots showing stimulated versus baseline abundances across individuals (solid line indicates  
585 significant relationship between baseline and stimulated abundance; dashed line indicates  
586 slope equal to one for reference). In the case of the convergent category, which only included  
587 a total of six annotated markers, all markers are listed. Ontology terms of interest, from an  
588 enrichment analysis performed on all markers within a category (where possible), are also  
589 included (immune-related terms in black).

590



591 **Fig. 3 Map of the T-cell receptor signalling KEGG pathway for *Mus musculus*, with the**  
592 **colour of nodes representing level of inter-individual variability in response to**  
593 **stimulation with anti-CD3 and anti-CD28 antibodies in *Microtus agrestis*.** Namely the *p*-  
594 value from an asymptotic test for the equality of variance in gene expression levels for  
595 baseline and stimulated samples (range = < 0.001–0.97). Dark blue indicates high inter-  
596 individual variability in response, whereas light blue or white indicates low inter-individual  
597 variability in response. Grey nodes represent genes for which no information is available,  
598 either because they are unannotated in the *M. agrestis* genome, or because they are weakly  
599 expressed in the spleen.

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616 **Tables**

617

618 **Table 1 Table summarising the number of markers found in each of the three main**  
619 **categories of immune response. For each of these categories, the number of convergent**  
620 **and divergent markers is shown.**

621

<b>Immune response category</b>	<b>Total no. markers</b>	<b>No. convergent</b>	<b>No. divergent</b>
Uncorrelated	47	2	1
Constant	306	0	91
Baseline-dependent	699	5	47

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637


## Baseline-dependence

response  
 → increase in level  
 → decrease in level

### No response


$$y = mx + c$$

$m = 1$




### Uncorrelated response

$m = 0$  (not shown)




### Constant response

$m = 1$




### Baseline-dependent response

Linear  $m \neq 1$




Quadratic  $y = ax^2 + bx + c$



## Variability


### Convergent response

$CV_{base} > CV_{stim}$




### Divergent response

$CV_{stim} > CV_{base}$




Baseline-dependence

Uncorrelated response



<i>Mon2</i>	<i>Smarcc2</i>	mRNA splicing (4)
<i>Glyr1</i>	<i>Rbm5</i>	
<i>Setx</i>	<i>Ap3d1</i>	
<i>Baz2b</i>	<i>Zfp280d</i>	
<i>Clasp1</i>	<i>Zfp445</i>	


Constant response



<i>Lyst</i>	<i>Rapgef1</i>	TCR pathway (9) Natural killer cell mediated cytotoxicity (8) Fc epsilon RI signaling pathway (7) Fc gamma R-mediated phagocytosis (7) Insulin signaling pathway (9) thyroid hormone signaling pathway (8)
<i>Mgat4a</i>	<i>Swap70</i>	
<i>Rgs9</i>	<i>Ckap5</i>	
<i>Fyn</i>	<i>Sik3</i>	
<i>Ddr1</i>	<i>Hfe</i>	


Baseline-dependent response

Quadratic



<i>Cd247</i>	<i>Fam135a</i>	TCR pathway (7) Biological rhythms (6) RNA-mediated gene silencing (4)
<i>Snrk</i>	<i>Card11</i>	
<i>Cpd</i>	<i>Traf1</i>	
<i>Itga6</i>	<i>Sik2</i>	
<i>Cd3d</i>	<i>Ralgapa2</i>	


Linear



<i>Jchain</i>	<i>Cybb</i>	Immunity (20) Leukocyte transendothelial migration (14) T Cytotoxic Cell Surface Molecules (7) HTLV-I infection (20) Leukocyte cell-cell adhesion (7) Immunological synapse (6) Antigen processing and presentation of endogenous peptide antigen via MHC class I (4)
<i>Klri1</i>	<i>Ncf2</i>	
<i>Ikzf2</i>	<i>Cd8a</i>	
<i>Gbp2/2b</i>	<i>Tcf4</i>	
<i>Man2a2</i>	<i>Txndc5</i>	


Highly variable response

Divergent



<i>Mdn1</i>	<i>Jun</i>	Immunological synapse (5) Viral carcinogenesis (12) Epstein-Barr virus infection (11) Heat shock protein 70 family (4) Transcription factor Jun (3) Toxin transport (6) Positive regulation of telomere maintenance via telomerase (5)
<i>Xpo1</i>	<i>Ddx21</i>	
<i>Akap13</i>	<i>Usp28</i>	
<i>Serbp1</i>	<i>Hsph1</i>	
<i>Ptbp1</i>	<i>Sik2</i>	

Convergent



<i>Pdk1</i>	
<i>Ero1l</i>	
<i>Pja2</i>	
<i>Lonp1</i>	
<i>Mon2</i>	
<i>Tcirg1</i>	

Variability

